Sanofi's New CEO Paul Hudson Poised To Write The Next Chapter
Less than one month into the job, Sanofi CEO Paul Hudson talked about his early perspective on how he can build on Sanofi's strengths and deliver needed changes.
You may also be interested in...
Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.
Sanofi and US start-up Aetion are to collaborate on integrating their real-world evidence and analytics platforms to improve the clinical development process.